Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer

被引:68
作者
McArdle, Peter A. [1 ]
Mir, Khurram
Almushatat, A. S. K.
Wallace, A. Michael
Underwood, Mark A.
McMillan, Donald C.
机构
[1] Glasgow Royal Infirm, Dept Surg, Glasgow G31 2ER, Lanark, Scotland
[2] Glasgow Royal Infirm, Dept Biochem, Glasgow G31 2ER, Lanark, Scotland
[3] Glasgow Royal Infirm, Dept Urol, Glasgow G31 2ER, Lanark, Scotland
关键词
prostate cancer; metastases; prostate-specific antigen; C-reactive protein;
D O I
10.1159/000093905
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. It is increasingly recognised that, in cancer patients, disease progression is dependent on a complex interaction of the tumour and the host inflammatory response and that the systemic inflammatory response, as evidenced by an elevated C-reactive protein (CRP) concentration, may be a useful prognostic factor. Materials and Methods: The prognostic value of CRP compared with prostate-specific antigen (PSA) was examined in 62 patients with metastatic prostate cancer receiving androgen-deprivation therapy. Results: In all, 41 (66%) of patients died, 38 (61%) of their disease. On univariate survival analysis, PSA (p < 0.05) and CRP (p < 0.05) were significant predictors of cancer-specific survival. On multivariate analysis, both PSA (HR 1.96, 95% CI 1.00-3.83, p = 0.049) and CR (HR 1.97, 95% CI 0.99-3.92, p = 0.052) were independent predictors of cancer-specific survival. PSA concentrations were significantly correlated with those of CRP (rs = 0.46, p < 0.001). Conclusion:The results of the present study suggest that, in patients with metastatic prostate cancer, the presence of an elevated CRP concentration predicts poor outcome, independent of PSA. Copyright (c) 2006 S. Karger AG, Basel
引用
收藏
页码:127 / 129
页数:3
相关论文
共 17 条
[11]   Prognostic factors in advanced cancer patients:: Evidence-based clinical recommendations -: A study by the Steering Committee of the European Association for Palliative Care [J].
Maltoni, M ;
Caraceni, A ;
Brunelli, C ;
Broeckaert, B ;
Christakis, N ;
Eychmueller, S ;
Glare, P ;
Nabal, M ;
Viganò, A ;
Larkin, P ;
De Conno, F ;
Hanks, G ;
Kaasa, S .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6240-6248
[12]   The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease [J].
McArdle, PA ;
McMillan, DC ;
Sattar, N ;
Wallace, AM ;
Underwood, MA .
BRITISH JOURNAL OF CANCER, 2004, 91 (10) :1755-1757
[13]   The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer [J].
McKeown, DJ ;
Brown, DJF ;
Kelly, A ;
Wallace, AM ;
McMillan, DC .
BRITISH JOURNAL OF CANCER, 2004, 91 (12) :1993-1995
[14]  
Nakashima J, 2000, CLIN CANCER RES, V6, P2702
[15]   Prognostic factors in advanced gastrointestinal cancer patients with weight loss [J].
O'Gorman, P ;
McMillan, DC ;
McArdle, CS .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2000, 37 (01) :36-40
[16]  
Okamoto M, 1997, CANCER RES, V57, P141
[17]   AN EVALUATION OF SERUM-PROTEIN PROFILES IN THE LONG-TERM SURVEILLANCE OF PROSTATIC-CANCER [J].
TRAUTNER, K ;
COOPER, EH ;
HAWORTH, S ;
WARD, AM .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1980, 14 (02) :143-149